Anlotinib plus PD-1 inhibitor in advanced soft tissue sarcoma: a real-world study on treatment patterns and treatment-emergent hypothyroidism.
- DOI
- 10.3389/fimmu.2026.1949174
- Published
- 2026
- Container
- Frontiers in immunology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2026.1949174,
title = {Anlotinib plus PD-1 inhibitor in advanced soft tissue sarcoma: a real-world study on treatment patterns and treatment-emergent hypothyroidism.},
author = {Wu F and Zhu WT and Li YZ and Zheng Y and Zhang HM and Wang XW},
year = {2026},
journal = {Frontiers in immunology},
doi = {10.3389/fimmu.2026.1949174},
url = {https://doi.org/10.3389/fimmu.2026.1949174}
}RIS
TY - JOUR TI - Anlotinib plus PD-1 inhibitor in advanced soft tissue sarcoma: a real-world study on treatment patterns and treatment-emergent hypothyroidism. AU - Wu F AU - Zhu WT AU - Li YZ AU - Zheng Y AU - Zhang HM AU - Wang XW PY - 2026 JO - Frontiers in immunology DO - 10.3389/fimmu.2026.1949174 UR - https://doi.org/10.3389/fimmu.2026.1949174 ER -
APA
F, W., WT, Z., YZ, L., Y, Z., HM, Z., & XW, W. (2026). Anlotinib plus PD-1 inhibitor in advanced soft tissue sarcoma: a real-world study on treatment patterns and treatment-emergent hypothyroidism.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1949174